A new Covid “vaccine” is advancing through clinical trials in the United States, but this time it’s not a shot in the arm, it’s a “breathable” mist that “vaccinates” people by entering the lungs.
In what researchers are calling a “first-of-its-kind” study, a team at Cincinnati Children’s Hospital, led by Dr. Paul Spearman, has released early trial results on a Covid “vaccine” spray.
The study was funded by CyanVac LLC and published in Science Advances.
The candidate, called CVXGA1, is delivered via nasal spray, directly into the mucous membranes.
The atomized “vaccine” is being touted as the next frontier in pandemic “prevention.”
However, while legacy media and government researchers call the results “encouraging,” the trial and the technology behind it raise major concerns about safety, transparency, and future public health policy, particularly among Americans who’ve already been burned by broken vaccine promises.
The study involved just 72 people, aged 12–53, and aimed to test how the human body responds to live virus vectors sprayed directly into the respiratory system.
Participants received either low or high doses of the nasal vaccine and were monitored for adverse events and immune responses.
Among those who received higher doses, mild side effects such as